Table 3.
Significant predictors for composite cardiac endpoint: results of multivariate Cox-regression analysis
| Variable | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Whole subjects | ||||
| Age, 1 year increase | 1.03 (1.01-1.05) | 0.001 | 1.02 (1.00-1.05) | 0.025 |
| Diabetes, presence | 2.85 (1.56-5.18) | 0.001 | 2.48 (1.27-4.86) | 0.008 |
| Statin, use | 1.26 (0.75-2.12) | 0.201 | - | - |
| Previous history of CAD, presence | 3.36 (2.01-5.41) | < 0.001 | 2.40 (1.29-4.47) | 0.006 |
| hs-CRP, 1 mg/L increase | 1.25 (1.01-1.53) | 0.030 | 1.25 (1.01-1.55) | 0.040 |
| LVEF < 50% vs. ≥ 50% | 2.50 (1.54-4.00) | < 0.001 | 1.99 (1.12-4.19) | 0.043 |
| Concentric LVH, presence | 2.02 (1.06-3.85) | 0.032 | 1.55 (1.05-2.85) | 0.058 |
| SSS < 4 | ||||
| Age, 1 year increase | 1.03 (1.01-1.06) | 0.010 | 1.04 (1.01-1.07) | 0.007 |
| Diabetes, presence | 3.89 (1.63-9.31) | 0.002 | 2.45 (1.01-5.61) | 0.034 |
| Statin, use | 1.10 (0.81-1.69) | 0.102 | - | - |
| Previous history of CAD, presence | 2.67 (1.23-5.83) | 0.013 | 4.17 (1.78-10.23) | 0.002 |
| hs-CRP, 1 mg/L increase | 1.46 (1.02-2.10) | 0.036 | 1.47 (1.01-2.09) | 0.042 |
| LVEF < 50% vs. ≥ 50% | 2.74 (1.33-5.65) | 0.006 | 2.47 (1.11-5.56) | 0.030 |
| Concentric LVH, presence | 2.01 (1.02-3.83) | 0.031 | 1.21 (1.02-1.68) | 0.016 |
HR, hazard ratio; CI, confidence intervals; CAD, coronary artery disease; hs-CRP, high-sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; SSS, summed stress score.